-
301
-
302
Global interest in vaccines during the COVID‐19 pandemic: Evidence from Google Trends
Published 2022-04-01Subjects: Get full text
Article -
303
Cell immunity to SARS-CoV-2 after natural infection and/or different vaccination regimens
Published 2024-03-01Subjects: Get full text
Article -
304
BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study
Published 2024-02-01Subjects: Get full text
Article -
305
-
306
Acute pancreatitis in pregnancy following COVID-19 vaccine: a case report
Published 2022-09-01Subjects: “…Pfizer-BioNTech (BNT162b2) mRNA vaccine…”
Get full text
Article -
307
Adverse Events and Immunogenicity of mRNA-Based COVID-19 Vaccine among Healthcare Workers: A Single-Centre Experience
Published 2022-03-01Subjects: Get full text
Article -
308
Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components
Published 2022-03-01“…The aim of this work has been to investigate the effects of BNT162b2 Pfizer-BioNTech mRNA-based vaccine booster dose in a cohort of 11 uninfected immunocompetent (ICs), evaluating the humoral and cellular responses, with more carefulness on memory B and T cells. …”
Get full text
Article -
309
Differences in B-Cell Immunophenotypes and Neutralizing Antibodies Against SARS-CoV-2 After Administration of BNT162b2 (Pfizer-BioNTech) Vaccine in Individuals with and without Prior COVID-19 - A Prospective Cohort Study
Published 2022-08-01“…José Javier Morales-Núñez,1 Mariel García-Chagollán,1 José Francisco Muñoz-Valle,1 Saúl Alberto Díaz-Pérez,1 Paola Carolina Torres-Hernández,2 Saraí Citlalic Rodríguez-Reyes,3 Guillermo Santoscoy-Ascencio,4 José Julio Sierra García de Quevedo,4 Jorge Hernández-Bello1 1Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara, Jalisco, Mexico; 2Immunology Laboratory, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara, Jalisco, Mexico; 3Institute of Translational Nutrigenetics and Nutrigenomics, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara, Jalisco, Mexico; 4Unidad de Patología Clinica (UPC), Guadalajara, Jalisco, MexicoCorrespondence: Jorge Hernández-Bello,s Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara, Jalisco, 44340, Mexico, Tel +52 3334509355, Email jorge.hernandezbello@cucs.udg.mxPurpose: Understanding the humoral immune response dynamics carried out by B cells in COVID-19 vaccination is little explored; therefore, we analyze the changes induced in the different cellular subpopulations of B cells after vaccination with BNT162b2 (Pfizer-BioNTech).Methods: This prospective cohort study evaluated thirty-nine immunized health workers (22 with prior COVID-19 and 17 without prior COVID-19) and ten subjects not vaccinated against SARS-CoV-2 (control group). …”
Get full text
Article -
310
-
311
-
312
-
313
Why COVID vaccines for young children (5–11 years) are not essential at this moment in time?
Published 2022-12-01Subjects: Get full text
Article -
314
Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern
Published 2022-01-01Subjects: Get full text
Article -
315
Generalized morphea following COVID‐19 vaccine: Case report and literature review
Published 2023-04-01Subjects: Get full text
Article -
316
Exploration of Correlations between COVID-19 Vaccination Choice and Public Mental Health Using Google Trend Search
Published 2022-12-01Subjects: Get full text
Article -
317
Vaccine Side Effects Following COVID-19 Vaccination Among the Residents of the UAE—An Observational Study
Published 2022-05-01Subjects: Get full text
Article -
318
Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
Published 2021-04-01Subjects: Get full text
Article -
319
Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
Published 2022-03-01“…Findings also suggest that a full course of the Pfizer-BioNTech provides the optimal protection against infection with the Delta variant. …”
Get full text
Article -
320